Best of ASH 2022 Webinar
Dr. Brian G.M. Durie discusses important takeaways relating to multiple myeloma from the annual American Society of Hematology (ASH) conference
The “Best of ASH 2022: What Patients and Care Partners Need to Know” will take place on Tuesday, December 20, 2022, at 4:00 p.m. PST | 6:00 p.m. CST | 7:00 p.m. EST. In this webinar, IMF Chairman of the Board and Chief Scientific Officer Dr. Brian G. M. Durie will summarize key takeaways from the 2022 American Society of Hematology (ASH) Annual Meeting that impact the myeloma community. Additionally, Dr. Durie will host a panel discussion highlighting the patient perspective with Linda Huguelet, IMF Support Group Leader of Chatanooga, TN; and Nick Lenoir, IMF Support Group Co-leader of Brooksville, FL. Both Linda and Nick are attending this year’s ASH annual meeting.
Of the more than 3,000 abstracts presented at the 2022 ASH meeting, 1,041 were related to multiple myeloma. Some of the topics of utmost interest to the myeloma community include the following:
- The use of TECVAYLI™ (teclistamab-cqyv), a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma
- A look at the MAIA Trial, which uses daratumumab, lenalidomide, and dexamethasone in transplant-ineligible patients
- A discussion of the GRIFFIN trial, which uses daratumumab, lenalidomide, bortezomib, and dexamethasone in newly diagnosed and transplant-eligible patients
- A consideration of how to reduce the incidence and severity of cytokine release syndrome by pretreating with tocilizumab prior to the CD3 bispecific cevostamab in patients with relapsed/refractory multiple myeloma
Dr. Durie explains this data in approachable terms that patients and care partners can use in their everyday care decision-making.
With Support from:
Bristol-Myers Squibb, GSK, Janssen Oncology, Karyopharm Therapeutics, Sanofi, Takeda Oncology